Ian Flinn, MD, PhD

Long-term follow-up data on BTK inhibitors reassures patients about safety and efficacy, guiding treatment decisions for chronic conditions.

Experts discuss the promising long-term results of zanubrutinib for high-risk CLL patients, emphasizing the importance of upfront biomarker testing.

Ian Flinn, MD, PhD; and Danielle Brander, MD, reflect on the key long-term findings from the SEQUOIA trial, with particular emphasis on durability of response and outcomes in high-risk patient populations.

In this segment, experts review 6-year follow-up data from the SEQUOIA and ALPINE studies in CLL and SLL, with a focus on efficacy, safety, and treatment selection in the modern era.

Dr. Ian Flinn spoke with Cancer Network about incorporating the newest approved therapies for the management of CLL.